# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price ta...
Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0....
Piper Sandler analyst Allison Bratzel maintains Roivant Sciences (NASDAQ:ROIV) with a Overweight and raises the price target...
Cantor Fitzgerald analyst Louise Chen reiterates Roivant Sciences (NASDAQ:ROIV) with a Overweight.
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price ta...
Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0....
BuzzFeed shares surged after Vivek Ramaswamy acquired a 7.7% stake for $3.2 million.